Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating activities    
Net loss $ (13,088) $ (23,075)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 153 138
Stock-based compensation expense 1,998 2,342
Net accretion and amortization of investments in marketable securities (205) (544)
Changes in assets and liabilities:    
Interest receivable and other current assets 310 (177)
Prepaid research and development expenses and other prepaid assets 1,951 (2,233)
Other assets   1,158
Accounts payable (1,290) 437
Accrued restructuring charges (1,476)  
Accrued liabilities (3,061) (440)
Net cash used in operating activities (14,708) (22,394)
Investing activities    
Purchases of property and equipment   (178)
Purchases of marketable securities (65,503) (90,897)
Proceeds from maturities of marketable securities 112,136 78,051
Proceeds from sale of marketable securities   3,980
Net cash provided by (used in) investing activities 46,633 (9,044)
Financing activities    
Proceeds from issuance of common stock, net of issuance costs   107,920
Proceeds from issuance of common stock pursuant to equity award plans   97
Cash provided by financing activities   108,017
Net increase in cash and cash equivalents 31,925 76,579
Cash and cash equivalents at beginning of period 24,869 48,995
Cash and cash equivalents at end of period 56,794 125,574
Supplemental disclosure    
Cash paid for amounts included in the measurement of lease liabilities $ 161 157
Supplemental non-cash investing and financing activities    
Accrued financing costs   $ 174